Ernexa Therapeutics Inc Ordinary Shares ERNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.27
- Day Range
- $4.08–4.24
- 52-Week Range
- $3.28–71.00
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 1.63M
- Market Cap
- $4.74M
- Volume/Avg
- 27,709 / 502,597
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.ernexatx.com
Valuation
|
Metric
|
ERNA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.51 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ERNA
Financial Strength
|
Metric
|
ERNA
|
|---|---|
Quick Ratio | 1.74 |
Current Ratio | 2.01 |
Interest Coverage | — |
Quick Ratio
ERNA
Profitability
|
Metric
|
ERNA
|
|---|---|
Return on Assets (Normalized) | −213.58% |
Return on Equity (Normalized) | −380.31% |
Return on Invested Capital (Normalized) | −343.98% |
Return on Assets
ERNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|%R$Htd | LOCK|h#md | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!fPWMr | LOCK|$NrqW | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#J<z!n | LOCK|kSR | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@%$xKkS | LOCK|$ljdf | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|GqR?^BC | LOCK|?& | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@^!bM? | LOCK|Mqv> | $31B | |||
| Moderna Inc
MRNA
| LOCK|SFgxPv# | LOCK|$s | $25B | |||
| Incyte Corp
INCY
| LOCK|!fglFBr | LOCK|$vh | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|SG<m>Z | LOCK|F!W | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|HyXP@> | LOCK|sm | $16B |
United States